Merck CEO Rob Davis has aggressively transformed the pharmaceutical giant into an industry dealmaker, spending almost $26 billion on acquisitions in the last year alone. This strategic pivot aims to diversify revenue streams away from Keytruda, the world’s top-selling drug, whose patent cliff looms in 2028. Investors have rewarded this proactive approach, pushing Merck’s share price up roughly 45% since last July.

Keytruda currently accounts for nearly half of Merck’s total revenue, creating an urgent need to fill that impending void, something no other CEO currently faces to this degree. Davis has focused on infectious diseases and respiratory treatments, securing bolt-on biotechs like the $9.2 billion Cidara Therapeutics acquisition. This disciplined approach contrasts with the skipped, oversized bids, such as the potential $32 billion transaction with Revolution Medicines.

Shareholders view Davis’s activity favorably, contrasting Merck’s performance against rivals like Eli Lilly, which saw a 30% stock rise over the same period. While the enhanced pipeline now boasts 22 late-stage clinical medicines, analysts caution that the company’s narrative is still tethered to its oncology blockbuster. Successfully transitioning away from being perceived as a “one-drug company” requires delivering on these newer ventures, particularly as the FDA reviews pending approvals for HIV and heart disease treatments.

Merck’s recent M&A activity, including the $6.7 billion takeover of Terns Pharmaceuticals, signals a clear intent to build a broader portfolio. The firm successfully navigated pricing threats and regulatory uncertainty plaguing the sector. Davis maintains conviction in the scientific pipeline developed through these targeted transactions, solidifying the firm's current valuation premium.